JP2015518053A - 癌の治療のためのａｍｇ９００の使用 - Google Patents

癌の治療のためのａｍｇ９００の使用 Download PDF

Info

Publication number
JP2015518053A
JP2015518053A JP2015515210A JP2015515210A JP2015518053A JP 2015518053 A JP2015518053 A JP 2015518053A JP 2015515210 A JP2015515210 A JP 2015515210A JP 2015515210 A JP2015515210 A JP 2015515210A JP 2015518053 A JP2015518053 A JP 2015518053A
Authority
JP
Japan
Prior art keywords
cancer
amg900
days
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015515210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518053A5 (enExample
Inventor
フライバーグ，グレゴリー
ペイトン，マーク
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2015518053A publication Critical patent/JP2015518053A/ja
Publication of JP2015518053A5 publication Critical patent/JP2015518053A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015515210A 2012-05-31 2013-05-30 癌の治療のためのａｍｇ９００の使用 Pending JP2015518053A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654021P 2012-05-31 2012-05-31
US61/654,021 2012-05-31
PCT/US2013/043468 WO2013181462A1 (en) 2012-05-31 2013-05-30 Use of amg 900 for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018076981A Division JP2018138570A (ja) 2012-05-31 2018-04-12 癌の治療のためのａｍｇ９００の使用

Publications (2)

Publication Number Publication Date
JP2015518053A true JP2015518053A (ja) 2015-06-25
JP2015518053A5 JP2015518053A5 (enExample) 2016-07-14

Family

ID=48614183

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015515210A Pending JP2015518053A (ja) 2012-05-31 2013-05-30 癌の治療のためのａｍｇ９００の使用
JP2018076981A Pending JP2018138570A (ja) 2012-05-31 2018-04-12 癌の治療のためのａｍｇ９００の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018076981A Pending JP2018138570A (ja) 2012-05-31 2018-04-12 癌の治療のためのａｍｇ９００の使用

Country Status (5)

Country Link
US (2) US8921367B2 (enExample)
EP (1) EP2854811A1 (enExample)
JP (2) JP2015518053A (enExample)
TW (1) TW201410246A (enExample)
WO (1) WO2013181462A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530527A (ja) * 2015-08-27 2018-10-18 イーライ リリー アンド カンパニー Ｅｚｈ２の阻害剤
JP2023505239A (ja) * 2019-12-03 2023-02-08 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド 新規オーロラキナーゼ阻害剤およびその使用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
AU2014357545B2 (en) 2013-12-03 2018-10-25 Amgen Inc. Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016164392A1 (en) 2015-04-06 2016-10-13 The Johns Hopkins University A h3t3a mutant protein efficiently reduces h3t3p and causes increased cell death of rapidly dividing cells
IL305368A (en) * 2021-03-17 2023-10-01 Amgen Inc Sutorsive dosing regimen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031842A1 (en) * 2009-09-11 2011-03-17 Amgen Inc. N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031842A1 (en) * 2009-09-11 2011-03-17 Amgen Inc. N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"抗悪性腫瘍薬の臨床評価方法に関するガイドライン", 薬食審査発第1101001号, JPN6017047035, 1 November 2005 (2005-11-01), ISSN: 0003697973 *
CANCER RESEARCH, vol. 70, no. 23, JPN6017003759, 1 December 2010 (2010-12-01), pages 9846 - 9854, ISSN: 0003494492 *
THE ONCOLOGIST, vol. 14, JPN6017003760, 2009, pages 780 - 793, ISSN: 0003494493 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530527A (ja) * 2015-08-27 2018-10-18 イーライ リリー アンド カンパニー Ｅｚｈ２の阻害剤
JP2023505239A (ja) * 2019-12-03 2023-02-08 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド 新規オーロラキナーゼ阻害剤およびその使用
US12275726B2 (en) 2019-12-03 2025-04-15 Wigen Biomedicine Technology (shanghai) Co., Ltd. Aurora kinase inhibitors and use thereof
JP7777528B2 (ja) 2019-12-03 2025-11-28 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド 新規オーロラキナーゼ阻害剤およびその使用

Also Published As

Publication number Publication date
JP2018138570A (ja) 2018-09-06
WO2013181462A1 (en) 2013-12-05
US8921367B2 (en) 2014-12-30
EP2854811A1 (en) 2015-04-08
TW201410246A (zh) 2014-03-16
US20130323198A1 (en) 2013-12-05
US20150079022A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
JP2018138570A (ja) 癌の治療のためのａｍｇ９００の使用
RU2492864C2 (ru) Способ лечения рака, несущего мутации egfr
TWI607754B (zh) 醫藥組合
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
JP2021502345A (ja) 抗がん剤
US20180353602A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
TW202210076A (zh) 組合療法
US11224608B2 (en) Compounds and methods for treating cancer
US20230118053A1 (en) Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
JP7703124B1 (ja) Ｓｅｒｄ投薬レジメンの組み合わせを使用してがんを治療する方法
JP2017521468A (ja) 組み合わせ療法
WO2024093681A1 (zh) 英菲格拉替尼在治疗胃癌和腺癌中的用途
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
TWI776451B (zh) Bcl-2/bcl-xl抑制劑之組合及相關用途
CN101528235A (zh) 作为vegfr3抑制剂的大环喹唑啉衍生物
WO2025217597A1 (en) A cdk9 inhibitor for use in the treatment of cancer in a subject having an asxl1 mutation
HK40031775B (en) Compounds and methods for treating cancer
HK40031775A (en) Compounds and methods for treating cancer
TW200831525A (en) Compositions including triciribine and one or more platinum compounds and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171212